ESC 365 - Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD.

Open Access

Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD.

Session: Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl

Topic: Cardiovascular Risk Assessment

Speaker: Professor P. Steg (Paris, FR)

Sponsored by Amarin Pharma, Inc.

Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor Philippe Gabriel Steg

Hopital Bichat, Paris (France)

47 presentations

8 followers

4 more presentations in this session

Welcome and Introductions, Program Overview.

Speaker: Professor P. Steg (Paris, FR)

Hypertriglyceridaemia as a Causal Factor and Target for Therapy.

Speaker: Professor B. Nordestgaard (Copenhagen, DK)

Practical Considerations on Using Omega-3 Fatty Acids to Prevent ASCVD.

Speaker: Professor B. Nordestgaard (Copenhagen, DK)

Live Q&A and Adjourn.

Speaker: Professor P. Steg (Paris, FR) Professor B. Nordestgaard (Copenhagen, DK)

Access the full session

Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl

Speakers: Professor P. Steg, Professor P. Steg, Professor B. Nordestgaard, Professor B. Nordestgaard, Professor P. Steg...

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Related content

ESC Premium Access

Secondary mitral regurgitation from the perspective of left ventricular size and function.

27 August 2021

ESC Premium Access

Will coronary atherosclerosis be eliminated?

27 August 2021

ESC Premium Access

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

27 August 2021

ESC 365 is supported by